Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 5,923 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Hypersensitivity, Immediate Hypersensitivity, Food Hypersensitivity
Interventions: Egg oral immunotherapy, Control Group; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 18 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 5
States / cities: Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more

Conditions: Bruxism, Sleep-Related
Interventions: Not listed
Lead sponsor: Otis Dental, LLC; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Allergy
Interventions: Short Ragweed Pollen Allergenic Extract, Placebo; Biological
Lead sponsor: Greer Laboratories; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Warrenton, Virginia

Conditions: Other Disorders of Bone Development and Growth
Interventions: Combined Oral Contraceptive (COC), Contraceptive Vaginal Ring (CVR); Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: HIV-associated Lipodystrophy Syndrome
Interventions: GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Parotid Salivary Dysfunction
Interventions: Gene Transfer, AdhAQP1; Genetic · Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyponatremia
Interventions: Tolvaptan; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 4 Weeks to 17 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 5
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • New York, New York + 2 more

Conditions: Oral Cavity Carcinoma, Oral Intraepithelial Neoplasia
Interventions: Laboratory Biomarker Analysis, Patient Observation, Pembrolizumab; Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Vulvovaginal Candidiasis
Interventions: VT-1161, Placebo; Drug
Lead sponsor: Viamet; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 27 more

Conditions: Obesity, Overweight, Chronic Weight Management
Interventions: ASC30 tablets A1, Placebo; Drug
Lead sponsor: Ascletis Pharma (China) Co., Limited; Industry
Eligibility: 18 Years and older
Enrollment: 3,003 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 69
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more

Conditions: Chronic Weight Management
Interventions: ASC36 tablets, for oral use, ASC36 placebo tablets; Drug
Lead sponsor: Ascletis Pharma (China) Co., Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Lung Cancer, Precancerous Condition, Tobacco Use Disorder
Interventions: calcitriol, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 40 Years to 79 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Peri-Implantitis
Interventions: Standard mechanical debridement, Er:YAG laser-assisted debridement; Other · Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pain Management
Interventions: Ibuprofen, APAP; Drug
Lead sponsor: Antonios Likourezos; Other
Eligibility: 3 Years to 17 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo; Drug · Other
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 23
States / cities: Phoenix, Arizona • Centennial, Colorado • Fort Collins, Colorado + 20 more

Conditions: Periodontal Disease
Interventions: Periodontal therapy; Other
Lead sponsor: The Forsyth Institute; Other
Eligibility: 25 Years and older
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 5
States / cities: Edwardsville, Illinois • Cambridge, Massachusetts • Ann Arbor, Michigan + 2 more

Conditions: Breast Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer, Thyroid Cancer, Gynecologic Cancer, Pancreatic Cancer, Stomach Cancer, Brain Tumor, Colon Cancer, Rectal Cancer, Head and Neck Cancer, Oral Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Testicular Cancer, Solid Tumor
Interventions: Brodalumab, CT scan; Drug · Radiation
Lead sponsor: Brian Henick, MD; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: sarilumab SAR153191 (REGN88), simvastatin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Duncansville, Pennsylvania • Jackson, Tennessee • Dallas, Texas

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068, Oral Contraceptive, Loestrin 1.5/30; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Miami, Florida • San Antonio, Texas

Conditions: Obesity, Contraception
Interventions: UPA-ECx1, UPA-ECx2; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: LGD-6972 Solution, LGD-6972 Capsules; Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Dehydration
Interventions: Oral Rehydration Solution (ORS), Water; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine at bedtime instead of NPH, NPH twice-daily; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Idiopathic Hypersomnia
Interventions: Pentetrazol (PTZ), Placebo oral capsule; Drug
Lead sponsor: Balance Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 32
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Orange, California + 28 more

Search by objective public record fields.

Oral Immunotherapy for Childhood Egg Allergy

A Sensor-enhanced Mouth Guard to Quantitatively Measure Bite Compression Forces.

Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy

Assessing the Impact of Contraceptives on Bone Health Using 41Ca

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck Cancer

Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia

Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia

A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC36 Tablets for Oral Use in Adult Participants With Obesity or Overweight

Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer

Laser-Assisted Regenerative Surgical Therapy for Peri-implantitis

IBUPAP Study for Pain Management in Children

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

Biomarkers of Periodontal Disease Progression

Brodalumab in the Treatment of Immune-Related Adverse Events

Sarilumab Effect on the Pharmacokinetics of Simvastatin

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

Oral Rehydration Solution and Dehydration Recovery

Insulin Glargine Versus Twice-Daily NPH

A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia